Zanidatamab with pembrolizumab and chemo for HER2+ and PD-L1+ stomach cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new combination of targeted therapy (zanidatamab), immunotherapy (pembrolizumab), and chemotherapy for people with HER2-positive and PD-L1-positive advanced stomach or gastroesophageal cancer. It aims to see if this combination is more effective than current treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced or metastatic stomach or gastroesophageal cancer that is HER2-positive (a specific protein on cancer cells) and PD-L1-positive (another protein that helps cancer hide from the immune system).
- You have not had prior treatment for advanced or metastatic disease, but prior adjuvant or neoadjuvant therapy is allowed if it ended at least 6 months ago.
- You are 18 years or older and have a good performance status (able to care for yourself).
- Your liver, kidney, and blood cell counts are within acceptable ranges as defined by blood tests.
- You do not have untreated brain metastases, active autoimmune disease, or serious uncontrolled infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests adding a new drug (zanidatamab) to standard chemotherapy (paclitaxel and ramucirumab) for people with advanced HER2-positive stomach, gastroesophageal junction, or esophageal cancer that has worsened after previous treatment. It aims to see if the combination works better.
This trial tests a combination of two medications (zanidatamab and tislelizumab) for people with HER2-positive gastrointestinal cancers. It aims to see if this treatment can shrink tumors or prevent recurrence in early-stage cancers, and provide a new option for advanced colorectal cancer.
This trial tests a new drug called zanidatamab given together with standard chemotherapy before surgery for a type of stomach or junction cancer that is HER2-positive (has a specific protein). The goal is to see if this combination can shrink the tumor and improve the chances of successful surgery.
This trial tests whether a targeted drug (zanidatamab, which attacks HER2-positive cancer cells) combined with chemotherapy can shrink stomach cancer before surgery, making it easier to remove. It may also help people whose cancer has spread a bit, by making it operable.
This study tests whether adding a new targeted drug called zanidatamab to standard chemotherapy before and after surgery can improve the chances of getting rid of HER2-positive stomach or esophageal cancer. It is designed for patients whose cancer can still be removed with surgery and has not spread.
This trial tests a drug called zanidatamab for people with advanced solid tumors that have a specific marker called HER2. It may help if you've already tried one or more standard treatments.
Hear when a new Gastroesophageal Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.